rofecoxib has been researched along with Malignant Melanoma in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 9.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| " Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells." | 7.96 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimović-Ivanić, D; Mijatović, S; Murganić, B; Neumann, W; Paskaš, S; Pietzsch, J; Sárosi, MB, 2020) |
| "A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21)." | 7.72 | Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Krause, SW; Reichle, A; Vogt, T; Wild, P, 2004) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 5.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| " Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells." | 3.96 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimović-Ivanić, D; Mijatović, S; Murganić, B; Neumann, W; Paskaš, S; Pietzsch, J; Sárosi, MB, 2020) |
| " Here we report on a patient with a metastatic melanoma of the leg who experienced a complete and sustained regression of skin metastases upon continuous single treatment with the cyclooxygenase-2 inhibitor rofecoxib." | 3.73 | Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. ( Lejeune, FJ; Monnier, Y; Rüegg, C, 2006) |
| "A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21)." | 3.72 | Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Krause, SW; Reichle, A; Vogt, T; Wild, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buzharevski, A | 1 |
| Paskaš, S | 1 |
| Sárosi, MB | 1 |
| Laube, M | 1 |
| Lönnecke, P | 1 |
| Neumann, W | 1 |
| Murganić, B | 1 |
| Mijatović, S | 1 |
| Maksimović-Ivanić, D | 1 |
| Pietzsch, J | 1 |
| Hey-Hawkins, E | 1 |
| Spieth, K | 1 |
| Kaufmann, R | 1 |
| Gille, J | 1 |
| Reichle, A | 2 |
| Bross, K | 1 |
| Vogt, T | 2 |
| Bataille, F | 1 |
| Wild, P | 1 |
| Berand, A | 2 |
| Krause, SW | 1 |
| Andreesen, R | 2 |
| Lejeune, FJ | 1 |
| Monnier, Y | 1 |
| Rüegg, C | 1 |
| Coras, B | 1 |
| Terheyden, P | 1 |
| Neuber, K | 1 |
| Trefzer, U | 1 |
| Schultz, E | 1 |
| Bröcker, EB | 1 |
| Landthaler, M | 1 |
2 trials available for rofecoxib and Malignant Melanoma
| Article | Year |
|---|---|
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Cell Division; Cell Survival; C | 2003 |
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Che | 2007 |
3 other studies available for rofecoxib and Malignant Melanoma
| Article | Year |
|---|---|
Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.
Topics: Antineoplastic Agents; Boron Compounds; Carcinogenesis; Cell Line, Tumor; Colonic Neoplasms; Cycloox | 2020 |
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2004 |
Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor.
Topics: Aged; Cyclooxygenase 2 Inhibitors; Female; Humans; Lactones; Melanoma; Remission Induction; Skin Neo | 2006 |